Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

In human T-cell acute lymphoblastic leukemia (T-ALL), β-hydroxybutyrate dehydrogenase 1, the metabolic enzyme responsible for cell-autonomous BHB synthesis shows elevated protein expression without a corresponding increase at the mRNA level. We reasoned that BDH1 is deregulated is dysregulated post-transcriptionally and sought to identify the regulatory factors that sustain its aberrant protein expression.

ABSTRACT: In human T-cell acute lymphoblastic leukemia (T-ALL), β-hydroxybutyrate dehydrogenase 1, the metabolic enzyme responsible for cell-autonomous BHB synthesis shows elevated protein expression without a corresponding increase at the mRNA level. We reasoned that BDH1 is deregulated is dysregulated post-transcriptionally and sought to identify the regulatory factors that sustain its aberrant protein expression.To identify BDH1 interacting proteins, total cellular proteins extracted from T-ALL cells overexpressing either the pHAGE vector or pHAGE-BDH1 were subjected to immunoprecipitation and were subjected to LC-MS.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Culture

SUBMITTER: Jin Xu

LAB HEAD: Hudan Liu

PROVIDER: PXD068682 | Pride | 2025-12-09

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	Human-BDH1-1.raw	Raw
	Human-BDH1-1.xlsx	Xlsx
	Human-BDH1-2.raw	Raw
	Human-BDH1-2.xlsx	Xlsx
	Human-BDH1-3.raw	Raw

Items per page:

1 - 5 of 13

Similar Datasets

Effect of BHB on transcriptional changes of antigen-stimulated CART19 cells

Project description:This study examines the impact of β-hydroxybutyrate (BHB) on T cell function using RNA-seq, ATAC-seq, and H3K27ac CUT&RUN profiling to characterize BHB-induced transcriptional and epigenetic remodeling.

2025-12-09 | GSE312333 | GEO

Downregulation of HDAC9 by β-hydroxybutyrate suppresses vascular calcification in chronic kidney disease

Project description:In this study, we report the protective effect of β-hydroxybutyrate (BHB) on vascular calcification in chronic kidney disease (CKD). To further investigate the mechanism underpinning the protective effect of BHB on vascular calcification, we performed high-throughput RNA-seq to identify the target gene of BHB. Our data demonstrate that BHB supplementation inhibits vascular calcification in CKD via targeting HDAC9.

2021-11-01 | GSE186772 | GEO

Preliminary Investigation of β-hydroxybutyrate Supplementation in Colorectal Cancer Prevention

Project description:The aim of this study is to assess the feasibility of beta-hydroxybutyrate (BHB) supplementation in individuals who are undergoing a standard-of-care colonoscopy or flexible sigmoidoscopy.

| 2719536 | ecrin-mdr-crc

Quantitative Proteomics Analysis Expands the Roles of Lysine -Hydroxybutyrylation Pathway in Response to Environmental β-Hydroxybutyrate

Project description:Lysine -hydroxybutyrylation (Kbhb) is a newly identified protein post-translational modification that derived from the ketone body β-hydroxybutyrate (BHB). BHB is synthesized in the liver from fatty acids and could be delivered to peripheral tissues when the supply of glucose is too low for the body’s energetic needs. The plasma concentration of BHB can increase up to 20 mM during starvation and in pathological conditions. Despite the progresses, how the cells that do not produce BHB respond to elevated environmental BHB remains largely unknown. Given that BHB significantly drives Kbhb, here we performed a quantitative proteomics study to characterize the BHB-induced lysine -hydroxybutyrylome and acetylome. A total of 840 unique Kbhb sites across 429 proteins were identified, with 42 sites from 39 proteins being increased by more than 50% in response to BHB. The upregulated β-hydroxybutyrylome induced by BHB are involved in aminoacyl-tRNA biosynthesis, 2-oxocarboxylic acid metabolism, citrate cycle (TCA cycle), glycolysis/gluconeogenesis, and pyruvate metabolism pathways. Moreover, some BHB-targeted Kbhb substrates are potentially linked to diseases such as cancer. Taken together, this study revealed the dynamics of lysine -hydroxybutyrylome and acetylome in response to environmental BHB, which sheds light on the roles for Khib in regulation of diverse cellular processes and provides new insights into the biological functions of BHB.

2022-04-04 | PXD029481 | Pride

Fam172a deletion in brown adipose tissue protects against HFD-induced obesity by activating the BDH1-BHB pathway

Project description:Family with sequence similarity 172 member A (FAM172A) protein acts as a key physiological repressor of brown adipose tissue (BAT) activity that plays a key role in energy metabolism. Its expression in BAT is suppressed by cold and other adrenergic stimulators. Mechanistically, FAM172A inhibits BAT activity and thermogenesis, in part, by binding to 3-hydroxybutyrate dehydrogenase 1 (BDH1), which subsequently affects the levels of beta-hydroxybutyrate (BHB), a ketone body metabolite closely involved in adipose mitochondrial biogenesis.

2023-08-29 | GSE241732 | GEO

KAT7 coupled with ACSS2 boosts transcription through regulation of histone β-hydroxybutyrylation [ChIP-seq]

Project description:Histone lysine β-hydroxybutyrylation (Kbhb) links ketone metabolism to gene transcription. However, the regulatory mechanism that kenogenesis-derived β-hydroxybutyrate, present throughout cells at low concentration, orchestrates this histone mark remains largely unknown. Here, we unveil a KAT7-ACSS2 module in which ACSS2 locally generates β-hydroxybutyryl-CoA (BHB-CoA), thereby bolsters histone Kbhb through fueling KAT7. Specifically, we show that KAT7 serves as a histone β-hydroxybutyryltransferase that prefers to modulate β-hydroxybutyrylation on histone H3 lysine 9 (H3K9bhb) by utilizing ACSS2-directed BHB-CoA. Moreover, ACSS2 senses β-hydroxybutyrate and translocates into the nucleus wherein it binds to and colocalizes with KAT7 at gene promoter regions. We further show that KAT7 coupled with ACSS2 regulates specific activation of genes associated with tumor cell survival through histone Kbhb. Collectively, our findings reveal that KAT7-ACSS2 module promotes histone β-hydroxybutyrylation by providing BHB-CoA locally, highlighting the importance of linking metabolic enzyme ACSS2 and KAT7 for histone Kbhb as well as offering insight into the regulatory mechanism of cellular metabolite on epigenetic modification and gene transcription.

2025-07-02 | GSE267130 | GEO

KAT7 coupled with ACSS2 boosts transcription through regulation of histone β-hydroxybutyrylation [RNA-seq]

2025-07-02 | GSE267129 | GEO

Beta-hydroxybutyrate is a metabolic regulator of proteostasis in aging and Alzheimer disease

Project description:Beta-hydroxybutyrate (BHB) is a ketone body whose signaling effects are not well characterized. The Newman Lab has observed a shift in brain cellular protein solubility following BHB treatment in vitro and in vivo. In the brains of C57BL/6 mice that received a 7-day oral gavage of ketone ester, we have observed formation of insoluble aggregates compared to control (canola oil). In a separate analysis, we treated soluble neuronal lysate from older C57BL/6 mice with multiple concentrations of R-BHB, then separated the proteins which become insolubilized. Here we seek to understand the composition of these insoluble aggregates by mass spectrometry and which proteins remain soluble, as a function of R-BHB treatment concentration.

2023-03-20 | MSV000091514 | MassIVE

CDK4-driven ketogenesis rewires histone modification to promote leukemia

Project description:Ketogenic nutrition has shown promise as an adjunct to conventional cancer therapies, its efficacy varies across cancer types depending on their metabolic characteristics.1,2 How ketogenic metabolites affect tumorigenesis, and whether ketone metabolism becomes deregulated in cancer cells, remain incompletely understood. Using T-cell acute lymphoblastic leukemia (T-ALL) as a model, we demonstrate that the ketone body β-hydroxybutyrate (BHB) is elevated in cancer cells and exerts a strong pro-leukemogenic effect. Remarkably, the key ketogenic enzyme β-hydroxybutyrate dehydrogenase 1 (BDH1) is significantly upregulated, enabling carbohydrate-driven BHB synthesis in leukemia cells. Mechanistically, aberrant CDK4 activation enables direct phosphorylation of BDH1 and enhances its protein stability. BDH1-mediated production of BHB augments histone β-hydroxybutyrylation (Kbhb) and activates transcription of pro-leukemogenic genes. Either BDH1 deficiency or CDK4 inactivation significantly suppresses T-ALL progression in vivo. Notably, ketogenic diet markedly reduces the anti-leukemic efficacy of the clinically approved CDK4/6 inhibitor palbociclib. Together, these findings highlight how oncogenic CDK4 drives cancer cell ketogenesis through BDH1 phosphorylation and promotes tumor progression via an epigenetic mechanism. Moreover, the implementation of ketogenic nutrition in cancer therapy should be approached with caution and guided by the molecular pathogenesis of individual cancer types.

2025-12-09 | GSE311088 | GEO

Ketogenic regulation of histone modification by CDK4 promotes leukemogenesis [RNA-seq]

Project description:While ketogenic nutrition shows promise as an adjunct to conventional cancer therapies, its efficacy varies depending on the type of cancer and its specific metabolic characteristics. How ketone bodies affect tumorigenesis and how the ketogenic pathway becomes deregulated in cancer remain to be fully understood. Using T-cell acute lymphoblastic leukemia (T-ALL) as a model, we here demonstrate that ketogenic metabolite β-hydroxybutyrate (BHB) plays a remarkable pro-leukemogenic role in mice. T-ALL cells generally exhibited greater expression of β-hydroxybutyrate dehydrogenase (BDH1), the metabolic enzyme that leads to cell autonomous synthesis of BHB. Mechanistically, aberrant CDK4 activation enables direct phosphorylation of BDH1 at the serine 296 residue and enhances its protein stability. Importantly, BDH1 deficiency leads to robust growth inhibition and cell death of human T-ALL cells, and markedly impedes NOTCH1-induced T-ALL progression in mice. BDH1-mediated production of BHB enhances the histone modification of β-hydroxybutyrylation (Kbhb), thereby leading to transcriptional activation of pro-leukemogenic genes MYC and NKX3.1. These findings shed light on how oncogenic CDK4 deregulates ketogenesis and promotes leukemia progression via an epigenetic mechanism. Therefore, ketogenic diets or ketone supplements should be taken with caution by cancer patients. Therapeutic interventions targeting key ketogenic enzymes may hold great promise for leukemia treatment.

2025-12-09 | GSE270919 | GEO